Institution
Northwestern University
Education•Evanston, Illinois, United States•
About: Northwestern University is a education organization based out in Evanston, Illinois, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 75430 authors who have published 188857 publications receiving 9463252 citations. The organization is also known as: Northwestern & NU.
Topics: Population, Medicine, Cancer, Health care, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Neuraxial anesthesia and analgesia provide several advantages over systemic opioids, including superior analgesia, reduced blood loss and need for transfusion, decreased incidence of graft occlusion, and improved joint mobility following major knee surgery.
926 citations
••
926 citations
••
TL;DR: In this article, the authors compared mobilities calculated using the hard sphere projection approximation for a range of fullerenes (C20−C240) to those determined from trajectory calculations with a more realistic He−fullerene potential.
Abstract: In a number of recent studies, information about the structure of large polyatomic ions has been deduced from gas phase ion mobility measurements by comparing mobilities measured in helium to those estimated for assumed geometries using a hard sphere projection approximation. To examine the validity of this approach, we have compared mobilities calculated using the hard sphere projection approximation for a range of fullerenes (C20−C240) to those determined from trajectory calculations with a more realistic He−fullerene potential. The He−fullerene potential we have employed, a sum of two-body 6-12 interactions plus a sum of ion-induced dipole interactions, was calibrated using the measured mobility of C60+ in helium over an 80−380 K temperature range. For the systems studied, the long-range interactions between the ion and buffer gas have a small, less than 10%, effect on the calculated mobility at room temperature. However, the effects are not insignificant, and in many cases it will be necessary to cons...
925 citations
•
TL;DR: In this paper, the authors investigate the cause of the generalization drop in the large batch regime and present numerical evidence that supports the view that large-batch methods tend to converge to sharp minima of the training and testing functions.
Abstract: The stochastic gradient descent (SGD) method and its variants are algorithms of choice for many Deep Learning tasks. These methods operate in a small-batch regime wherein a fraction of the training data, say $32$-$512$ data points, is sampled to compute an approximation to the gradient. It has been observed in practice that when using a larger batch there is a degradation in the quality of the model, as measured by its ability to generalize. We investigate the cause for this generalization drop in the large-batch regime and present numerical evidence that supports the view that large-batch methods tend to converge to sharp minimizers of the training and testing functions - and as is well known, sharp minima lead to poorer generalization. In contrast, small-batch methods consistently converge to flat minimizers, and our experiments support a commonly held view that this is due to the inherent noise in the gradient estimation. We discuss several strategies to attempt to help large-batch methods eliminate this generalization gap.
925 citations
••
Memorial Sloan Kettering Cancer Center1, Cleveland Clinic2, Harvard University3, University of Michigan4, Northwestern University5, Duke University6, Wayne State University7, Medical University of South Carolina8, Roswell Park Cancer Institute9, Indiana University10, Stanford University11, Fox Chase Cancer Center12, Bristol-Myers Squibb13, Johns Hopkins University14
TL;DR: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.
Abstract: Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety. Results A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, a...
923 citations
Authors
Showing all 76189 results
Name | H-index | Papers | Citations |
---|---|---|---|
George M. Whitesides | 240 | 1739 | 269833 |
Ralph B. D'Agostino | 226 | 1287 | 229636 |
Daniel Levy | 212 | 933 | 194778 |
David Miller | 203 | 2573 | 204840 |
Ronald M. Evans | 199 | 708 | 166722 |
Michael Marmot | 193 | 1147 | 170338 |
Robert C. Nichol | 187 | 851 | 162994 |
Scott M. Grundy | 187 | 841 | 231821 |
Stuart H. Orkin | 186 | 715 | 112182 |
Michael A. Strauss | 185 | 1688 | 208506 |
Ralph Weissleder | 184 | 1160 | 142508 |
Patrick O. Brown | 183 | 755 | 200985 |
Aaron R. Folsom | 181 | 1118 | 134044 |
Valentin Fuster | 179 | 1462 | 185164 |
Ronald C. Petersen | 178 | 1091 | 153067 |